AtriCure, Inc. 10-Q Summary: Period Ended June 30, 2006
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for AtriCure, Inc., a Delaware corporation developing and selling surgical devices for the treatment of atrial fibrillation (AF). The reporting period covers the three and six months ended June 30, 2006. The company's primary products are the Isolator bipolar ablation systems, which accounted for 83% of revenue in the first half of 2006. As of June 30, 2006, the company had 166 employees and 12,127,446 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 |
|---|---|---|
| Revenues | $18,285,846 | $15,228,179 |
| Gross Profit | $14,900,688 (81% margin) | $11,330,538 (74% margin) |
| Net Loss | $(6,298,112) | $(4,709,016) |
| Loss Per Share (Basic/Diluted) | $(0.52) | $(2.50) |
| Cash and Cash Equivalents | $19,814,470 | $5,175,177 (Beginning of period) |
| Total Investments (Short & Long Term) | $6,965,669 | $6,369,234 (Short-term only at Dec 31, 2005) |
| Total Debt (Current & Long-term) | $1,245,026 | $1,383,232 (Dec 31, 2005) |
| Working Capital | $28,287,957 | $35,902,887 (Dec 31, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20% ($3.1 million) for the six months ended June 30, 2006, driven by a 23% increase in the volume of disposable products sold. International sales grew to $2.1 million (11.4% of total revenue) from $1.5 million in the prior year period.
- Margin Expansion: Gross margin improved from 74% to 81%. Cost of revenues decreased 13% despite higher volume, attributed to a 36% reduction in average cost per unit following the acquisition of Enable Medical Corporation in late 2005.
- Operating Expenses: Total operating expenses increased 55% to $21.8 million. Selling, general, and administrative (SG&A) expenses rose 55% to $16.0 million due to headcount expansion and marketing. Research and development (R&D) expenses increased 57% to $5.8 million to support clinical trials and new product development.
- Net Loss: The net loss widened to $6.3 million from $4.7 million. However, loss per share improved significantly to $(0.52) from $(2.50) due to a reverse stock split and the conversion of preferred stock to common stock in August 2005, which eliminated preferred stock interest expense of $1.95 million in the prior year.
- Cash Flow: Net cash used in operating activities increased to $6.2 million from $2.7 million, primarily due to the higher net loss and increased working capital requirements (inventory and accounts receivable).
Outlook, Risks, and Management Commentary
- Regulatory Status: Substantially all revenue is generated from the "off-label" use of AtriCure systems for AF treatment, as the systems are not yet FDA-approved for this specific indication. The company intends to seek FDA approval as early as 2010 following clinical trials (RESTORE-SR and RESTORE-SR II).
- FDA Inspection: The FDA conducted a "for cause" inspection in July 2006 regarding clinical studies and manufacturing quality. The FDA did not issue a Form 483 or formal observations but expects a written report with recommendations.
- Liquidity: Management believes current cash and investments ($25.0 million in cash/short-term investments plus $1.8 million long-term) are sufficient to meet needs for at least the next 12 months. The company has a $5.0 million credit facility with $1.3 million outstanding.
- Strategic Agreement: On July 18, 2006, the company entered an agreement with The Cleveland Clinic to create an Atrial Fibrillation Innovation Center. Over three years, AtriCure is required to expend up to $7.7 million in operating expenses and $4.8 million in capital expenses, while receiving up to $0.9 million in funding.
- Legal Proceedings: The company is involved in litigation with former European distributor Life Support Technology LST B.V. regarding distribution rights and unpaid obligations. AtriCure is defending the claims and has filed a counterclaim in Ohio state court.
- Seasonality: The company notes a historical decline in sales during the third quarter due to the elective nature of the procedures.
Investor Verification Checklist
- Off-Label Revenue Dependency: Verify the sustainability of revenue streams given that primary products are not FDA-approved for their main use case (AF treatment).
- Cash Burn Rate: Monitor the $6.2 million cash burn in operating activities over six months against the $25 million cash balance to assess runway.
- Regulatory Milestones: Track progress of the RESTORE-SR and RESTORE-SR II clinical trials and the timeline for FDA approval (targeted 2010).
- Legal Exposure: Review the status of the LST B.V. litigation and potential financial impact of the counterclaims.
- Expense Trajectory: Confirm if SG&A and R&D expenses will continue to outpace revenue growth, potentially widening the operating loss.